Drugs / 225Ac-FAPI-XT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07135128 | Oct 2024 → Jun 2026 overdue | neoplastic disease or syndrome | Xiaorong Sun | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-FAPI-XT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07135128 ↗ |
| Known as | XT117 | “Patients will receive \[225Ac\]Ac-FAPI-XT(XT117) administration at an interval of 6 weeks between each dose.” NCT07135128 ↗ |